Composition comprising a colloidal synthetic bioresorbable vector and a viral vector

Patent metadata

Field	Value
Publication number	US-9433674-B2
Application number	US-201514620920-A
Country	US
Kind code	B2
Filing date	Feb 12, 2015
Priority date	Nov 14, 2005
Publication date	Sep 6, 2016
Grant date	Sep 6, 2016

Abstract

A method of vaccination against a viral, bacterial or non-infectious disease includes administering an effective dose of a prime vaccine and then an effective dose of a boost vaccine. Each one of the prime vaccine and the boost vaccine includes an active principle. The prime vaccine includes, as the active principle, a colloidal synthetic bioresorbable vector that includes at least one protein substance. The boost vaccine includes, as the active principle, a viral vector that includes at least one nucleotide sequence which codes for a protein substance corresponding to the at least one protein substance of the synthetic vector.

First claim

The invention claimed is:

1. A method of vaccination against a viral, bacterial or non-infectious disease comprising administering an effective dose of a prime vaccine and then an effective dose of a boost vaccine, each one of the prime vaccine and the boost vaccine comprising an active principle, wherein:
the prime vaccine comprises, as the active principle, a colloidal synthetic bioresorbable vector comprising at least one protein substance attached to a synthetic vector by inclusion or bonding; and
the boost vaccine comprises, as the active principle, a viral vector comprising at least one nucleotide sequence which codes for a protein substance corresponding to the at least one protein substance of the colloidal synthetic bioresorbable vector.

2. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector is a vector of spherical nature.

3. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector is prepared from at least one polymer selected from the group consisting of poly(a-hydroxy acids), polyhydroxybutyric acids, polycaprolactones, polyorthoesters, and polyanhydrides.

4. The method according to claim 3 , wherein the polymer is selected from the group consisting of poly(D-lactic acid), poly(L-lactic acid), polyglycolic acid, a mixture of poly(D- and L-lactic acids), a mixture of poly(L-lactic acid) and polyglycolic acid, a mixture of poly(O-lactic acid) and polyglycolic acid, and a mixture of poly(D- and L-lactic acids) and polyglycolic acid.

5. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector is prepared from at least one natural polymer.

6. The method according to claim 5 , wherein the natural polymer is selected from the group consisting of hyaluronic acid, chitosan and dextran.

7. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector comprises protein substances of different types, each constituting an antigen associated with the same disease.

8. The method according to the claim 1 , wherein the viral vector is an adenovirus or a poxvirus.

9. The method according to claim 1 , wherein the viral vector is a Modified Vaccinia Virus Ankara.

10. The method according to claim 1 , wherein the viral vector is the adenovirus 5.

11. The method according to claim 1 , wherein the protein substances are of viral origin.

12. The method according to claim 11 , wherein the protein substances of viral origin are proteins from a virus selected from the group consisting of herpes viruses, hepatitis viruses, papilloma viruses (HPV), human immunodeficiency viruses (IV), human influenza viruses, and avian influenza viruses.

13. The method according to claim 1 , wherein the protein substance is an antigen associated with tumours.

14. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector has a submicron size.

15. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector has a diameter between 150 and 900 nm.

16. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector has a diameter between 250 and 700 nm.

17. The method according to claim 1 , wherein the colloidal synthetic bioresorbable vector is free of stabilizer and surfactant.

18. The method according to claim 1 , further comprising administering an additional dose of the prime vaccine before the boost vaccine is administered.

Assignees

• Centre Nat Rech Scient
• Centre Nat Rech Scient

Inventors

• Ataman-Onal Yasemin
• Delair Thierry
• Verrier Bernard

Classifications

• A61K2039/55505

  Inorganic adjuvants · CPC title

• C12N2740/16071

  Demonstrated in vivo effect · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title